학술논문
BET bromodomain inhibition blocks an AR-repressed, E2F1-activated treatment-emergent neuroendocrine prostate cancer lineage plasticity program
Document Type
Article
Author
Kim, D.-H.; Sun, D.; Jenkins, C.; Coleman, D.J.; Sampson, D.; Guan, X.; Urrutia, J.A.; Schwartzman, J.A.; Xia, Z.; Alumkal, J.J.; Storck, W.K.; Leng, K.W.; Kumaraswamy, A.; Rodansky, E.S.; Zhang, C.; Yates, J.A.; Spratt, D.E.; Bankhead, A.; Rao, A.; Beltran, H.; Labrecque, M.P.; Morrissey, C.; Corey, E.; Lucas, J.M.; Coleman, I.M.; Nelson, P.S.; Handelman, S.K.; Sexton, J.Z.; Aggarwal, R.; Feng, F.Y.; Small, E.J.; Abida, W.; Gesner, E.M.; Attwell, S.; Lakhotia, S.; Campeau, E.
Source
In: Clinical Cancer Research . (Clinical Cancer Research, 1 September 2021, 27(17):4923-4936)
Subject
Language
English
ISSN
15573265
10780432
10780432